Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine

Clin Vaccine Immunol. 2012 Oct;19(10):1697-9. doi: 10.1128/CVI.00381-12. Epub 2012 Aug 22.

Abstract

There is no FDA-approved vaccine for the potent plant toxin ricin. We have developed a recombinant ricin vaccine, RiVax. Without adjuvant it is safe and immunogenic in mice, rabbits, and humans. Based on our studies in mice, we now report the results of a small clinical trial with Alhydrogel-adsorbed RiVax.

Publication types

  • Clinical Trial, Phase I
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adsorption
  • Adult
  • Aluminum Hydroxide
  • Antibodies / immunology
  • Antibody Formation
  • Female
  • Humans
  • Male
  • Pilot Projects*
  • Ricin / antagonists & inhibitors
  • Ricin / immunology*
  • Vaccines* / administration & dosage
  • Vaccines* / adverse effects
  • Vaccines* / immunology
  • Vaccines, Synthetic / administration & dosage
  • Vaccines, Synthetic / adverse effects
  • Vaccines, Synthetic / immunology
  • Young Adult

Substances

  • Antibodies
  • RiVax
  • Vaccines
  • Vaccines, Synthetic
  • Aluminum Hydroxide
  • Ricin